カテゴリー： Transparency Market Research, 世界, 医療/バイオ

世界の糖尿病装置市場2022年-2031年：製品種類別（グルコースモニタリング装置、インスリン送達装置、糖尿病管理ソフトウェア、人工膵臓システム）

◆英語タイトル：Diabetes Devices Market (Product Type: Glucose Monitoring Devices, Insulin Delivery Devices, Diabetes Management Software, and Artificial Pancreas System) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Transparency Market Researchが発行した調査報告書（TMR23JN050）◆商品コード：TMR23JN050
◆発行会社（リサーチ会社）：Transparency Market Research
◆発行日：2022年10月7日
◆ページ数：211
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の市場調査レポートでは、世界の糖尿病装置市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、糖尿病装置の世界市場分析・予測、主要インサイト、製品種類別（グルコースモニタリング装置、インスリン送達装置、糖尿病管理ソフトウェア、人工膵臓システム）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局、糖尿病診療所/センター）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。また、企業情報として、Medtronic、Novo Nordisk A/S、Sanofi、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、Becton, Dickinson and Company、Tandem Diabetes Care, Inc.、Abbott Laboratories、Cellnovo、Insulet Corporation、LifeScan, Inc.、Owen Mumford Ltd.などがあります。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・糖尿病装置の世界市場分析・予測
・主要インサイト
・世界の糖尿病装置市場規模：製品種類別
- グルコースモニタリング装置の市場規模
- インスリン送達装置の市場規模
- 糖尿病管理ソフトウェアの市場規模
- 人工膵臓システムの市場規模
・世界の糖尿病装置市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
- 糖尿病診療所/センターチャネルの市場規模
・世界の糖尿病装置市場規模：地域別
- 北米の糖尿病装置市場規模
- ヨーロッパの糖尿病装置市場規模
- アジア太平洋の糖尿病装置市場規模
- 中南米の糖尿病装置市場規模
- 中東・アフリカの糖尿病装置市場規模
・競争状況

Diabetes Devices Market – Scope of Report
TMR’s report on global diabetes devices market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global diabetes devices market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global diabetes devices market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the diabetes devices market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global diabetes devices market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global diabetes devices market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global diabetes devices market.

The report delves into the competitive landscape of the global diabetes devices market. Key players operating in the global diabetes devices market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global diabetes devices market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market diabetes devices.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Diabetes Devices Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Diabetes Devices Market Analysis and Forecast, 2017–2031
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Technological Advancements
5.2. Value Chain Analysis
5.3. Estimated Number of People with Diabetes Worldwide and Per Region (Age 20-79 years)
5.4. Emerging Technologies in Diabetes Management
5.5. COVID-19 Impact Analysis
6. Global Diabetes Devices Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Glucose Monitoring Devices
6.3.1.1. Self-monitoring Blood Glucose Meters
6.3.1.2. Blood Glucose Testing Strips
6.3.1.3. Lancets
6.3.1.4. Continuous Glucose Monitoring Meters
6.3.2. Insulin Delivery Devices
6.3.2.1. Insulin Syringes
6.3.2.2. Insulin Pens
6.3.2.3. Insulin Pumps
6.3.3. Diabetes Management Software
6.3.4. Artificial Pancreas System
6.4. Market Attractiveness Analysis, by Product Type
7. Global Diabetes Devices Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.3.4. Diabetes Clinics/Centers
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Diabetes Devices Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Diabetes Devices Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product Type, 2017–2031
9.2.1. Glucose Monitoring Devices
9.2.1.1. Self-monitoring Blood Glucose Meters
9.2.1.2. Blood Glucose Testing Strips
9.2.1.3. Lancets
9.2.1.4. Continuous Glucose Monitoring Meters
9.2.2. Insulin Delivery Devices
9.2.2.1. Insulin Syringes
9.2.2.2. Insulin Pens
9.2.2.3. Insulin Pumps
9.2.3. Diabetes Management Software
9.2.4. Artificial Pancreas System
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.3.4. Diabetes Clinics/Centers
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Diabetes Devices Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2017–2031
10.2.1. Glucose Monitoring Devices
10.2.1.1. Self-monitoring Blood Glucose Meters
10.2.1.2. Blood Glucose Testing Strips
10.2.1.3. Lancets
10.2.1.4. Continuous Glucose Monitoring Meters
10.2.2. Insulin Delivery Devices
10.2.2.1. Insulin Syringes
10.2.2.2. Insulin Pens
10.2.2.3. Insulin Pumps
10.2.3. Diabetes Management Software
10.2.4. Artificial Pancreas System
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Diabetes Clinics/Centers
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Diabetes Devices Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017–2031
11.2.1. Glucose Monitoring Devices
11.2.1.1. Self-monitoring Blood Glucose Meters
11.2.1.2. Blood Glucose Testing Strips
11.2.1.3. Lancets
11.2.1.4. Continuous Glucose Monitoring Meters
11.2.2. Insulin Delivery Devices
11.2.2.1. Insulin Syringes
11.2.2.2. Insulin Pens
11.2.2.3. Insulin Pumps
11.2.3. Diabetes Management Software
11.2.4. Artificial Pancreas System
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.3.4. Diabetes Clinics/Centers
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Diabetes Devices Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2031
12.2.1. Glucose Monitoring Devices
12.2.1.1. Self-monitoring Blood Glucose Meters
12.2.1.2. Blood Glucose Testing Strips
12.2.1.3. Lancets
12.2.1.4. Continuous Glucose Monitoring Meters
12.2.2. Insulin Delivery Devices
12.2.2.1. Insulin Syringes
12.2.2.2. Insulin Pens
12.2.2.3. Insulin Pumps
12.2.3. Diabetes Management Software
12.2.4. Artificial Pancreas System
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.3.4. Diabetes Clinics/Centers
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Diabetes Devices Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2031
13.2.1. Glucose Monitoring Devices
13.2.1.1. Self-monitoring Blood Glucose Meters
13.2.1.2. Blood Glucose Testing Strips
13.2.1.3. Lancets
13.2.1.4. Continuous Glucose Monitoring Meters
13.2.2. Insulin Delivery Devices
13.2.2.1. Insulin Syringes
13.2.2.2. Insulin Pens
13.2.2.3. Insulin Pumps
13.2.3. Diabetes Management Software
13.2.4. Artificial Pancreas System
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.3.4. Diabetes Clinics/Centers
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Medtronic
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Novo Nordisk A/S
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Sanofi
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Eli Lilly and Company
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. F. Hoffmann-La Roche Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. Becton Dickinson and Company
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Tandem Diabetes Care, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Abbott Laboratories
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
14.3.9. Cellnovo
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Strategic Overview
14.3.10. Insulet Corporation
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Strategic Overview
14.3.11. LifeScan, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. SWOT Analysis
14.3.11.4. Strategic Overview
14.3.12. Owen Mumford Ltd.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. SWOT Analysis
14.3.12.4. Strategic Overview



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の糖尿病装置市場2022年-2031年：製品種類別（グルコースモニタリング装置、インスリン送達装置、糖尿病管理ソフトウェア、人工膵臓システム）(Diabetes Devices Market (Product Type: Glucose Monitoring Devices, Insulin Delivery Devices, Diabetes Management Software, and Artificial Pancreas System) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界のペットケア糖尿病薬市場2023-2031：製品タイプ別（インスリン製剤、SGLT2阻害剤、その他）、動物種類別（猫、犬）
  • デジタル糖尿病管理の世界市場予測（～2030）

    • ◆H&Iグローバルリサーチのお客様（例）◆